The clinical efficacy of terbinafine in the treatment of fungal infections of nails

Reviews in Contemporary Pharmacotherapy

Volumn 8, Issue 5, 1997, Pages 299-312

  Roberts, David T ^a  

^a SOUTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; GRISEOFULVIN; ITRACONAZOLE; TERBINAFINE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DERMATOMYCOSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNE DEFICIENCY; MAJOR CLINICAL STUDY; META ANALYSIS; MYCOSIS; NAIL INFECTION; ONYCHOMYCOSIS; REVIEW;

EID: 0030711088     PISSN: 09548602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Alpsoy E, Yilmaz E, Basaran E. Intermittent therapy with terbinafine for dermatophyte toe onychomycosis: a new approach. J Dermatol 1996; 23: 259-262.
2. André J, Achten G. Onychomycosis. Int J Dermatol 1987; 26: 481-490.
3. Arenas R, Dominguez-Cherit J, Fernandez LMA. Open randomized comparison of itraconazole versus terbinafine in onychomycosis. Int J Dermatol 1995; 34: 138-143.
4. Arikian SR, Einarson TR, Kobelt-Nguyen G et al. A multinational pharmaco-economic analysis of oral therapies for onychomycosis. Br J Dermatol 1994; 130 (Suppl 43): 35-44.
5. Baran R, De Doncker P. Lateral edge nail involvement indicates poor prognosis for treating onychomycosis with new systemic antifungals. Acta Derm Venereol 1996; 76: 82-83.
6. Baudraz-Rosselet F, Rakosi T, Wili PB, Kenzelmann R. Treatment of onychomycosis with terbinafine. Br J Dermatol 1992; 126 (Suppl 39): 40-46.
7. Beare JM, Gentles JC, Mackenzie DWR. Mycology. In: Rook A, Wilkinson DS, Ebling FJG, eds. Textbook of dermatology, Vol 1. Oxford: Blackwell, 1972: 694.
8. Bräutigam M, Nolting S, Schopf RE et al. Randomized double-blind comparison of terbinafine and itraconazole in the treatment of toenail tinea infection. Br Med J 1995; 311: 919-922. See also published erratum Br Med J 1995; 311: 1350.
9. Bräutigam M, Nolting S, Schopf RE et al. German randomized double-blind multicentre comparison of terbinafine and itraconazole for the treatment of toenail tinea infection. Br J Dermatol 1996; 134 (Suppl 46): 18-21.
10. Carvalho MT, Fischman O, Alchorne MM et al. Fungi on healthy nails of immunosuppressed patients with AIDS. An Bras Dermatol 1991; 66: 111-112.
11. Cox NH, Irving B. Cutaneous 'ringworm' lesions of Scopulariopsis brevicaulis. Br J Dermatol 1993; 129: 726-728.
12. B) dans une série de 50 onychomycoses à dermatophytes. Ann Dermatol Venereol 1994; 121: 15-20.
13. De Backer M, De Keyser P, De Vroey C, Lesalffre E. A 12-week treatment for dermatophyte toe onychomycosis: terbinafine 250 mg/day vs itraconazole 200mg/day: a double blind comparative trial. Br J Dermatol 1996; 134 (Suppl 46): 16-17.
14. De Cuyper C. Long-term evaluation of terbinafine 250 and 500 mg daily in a 16-week oral treatment for toenail onychomycosis. Br J Dermatol 1996; 135: 156-157.
15. Dykes PJ, Thomas R, Finlay AY. Determination of terbinafine in nail samples during systemic therapy for onychomycosis. Br J Dermatol 1990; 123: 481-486.
16. Einarson TR, Arikian SR, Shear NH. Cost-effectiveness analysis for onychomycosis therapy in Canada from a government perspective. Br J Dermatol 1994; 130 (Suppl 43): 32-34.
17. Einarson TR, Gupta AK, Shear NH, Arikian S. Clinical and economic factors in the treatment of onychomycosis. Pharmacoeconomics 1996; 9: 307-320.
18. Elewski BE, Hay RJ. Update on the management of onychomycosis: highlights of the Third Annual International Summit on Cutaneous Antifungal Therapy. Clin Infect Dis 1996; 23: 305-313.
19. English MP, Atkinson E. Nail mycology in chiropody patients. Br J Dermatol 1974; 91: 67-72.
20. Faergemann J, Andreson C, Hersle K et al. Double blind, parallel group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. 1995; 32: 750-753.
21. Galimberti R, Kowalczyk A, Flores V, Squiquera L. Onychomycosis treated with a short course of oral terbinafine. Int J Dermatol 1996; 35: 374-375.
22. Gentles JC, Evans EGV. Infection of feet, toenails with Hendersonula toruloidea. Sabouraudia 1970; 8: 72-75.
23. Georgii A, Korting HG. Antifungal susceptibility testing with dermatophytes. Mycoses 1991; 34: 193-199.
24. Goodfield MJD. Clinical results with terbinafine in onychomycosis. J Dermatol Treat 1990; 1 (Suppl 2): 55-57.
25. Goodfield MJD, Andrew L, Evans EGV. Short term treatment of dermatophyte onychomycosis with terbinafine. Br Med J 1992; 304: 1151-1154.
26. Goodfield MJD, Bosanquet N, Evans EGV. Cost effective clinical management of onychomycosis. Br J Med Econ 1994; 7: 15-23.
27. Goulden V, Goodfield MJD. Treatment of childhood dermatophyte infections with oral terbinafine. Peadiatr Dermatol 1995; 12: 53-54.
28. Haneke E, Tausch I, Bräutigam M, Weidinger G, Welzel D. Short duration treatment of fingernail dermatophytosis: a randomized double blind study with terbinafine and griseofulvin. J Am Acad Dermatol 1995; 32: 72-77.
29. Havu V, Heikkila H, Kuokkanen K et al. A study to compare the efficacy of terbinafine and fluconazole in patients with onychomycosis. Abstracts of European Academy of Dermatology and Venereology. Lisbon: October, 1996.
30. Heikkila H, Stubb S. The prevalence of onychomycosis in Finland. Br J Dermatol 1995; 133: 699-703.
31. Hofmann H, Brautigam M, Weidinger G et al. Treatment of toenail onychomycosis. A randomized, double-blind study with terbinafine and griseofulvin. Arch Dermatol 1995; 131: 919-922.
32. Hogan DJ. Short-duration treatment of fingernail dermatophytosis: a randomized, double-blind study with terbinafine and griseofulvin. J Am Acad Dermatol 1995; 32: 541-542.
33. Hughes JR, Pembroke AC. Microsporum canis infection of the thumb-nail. Clin Exp Dermatol 1994; 19: 281-282.
34. Jones TC. United Kingdom multicentre study. A double-blind comparison of terbinafine 250 mg daily vs 125 mg daily in onychomycosis. Data on file, Sandoz Pharmaceuticals, Basel, 1992.
35. Korting HC, Ollert M, Abeck D et al. Results of German multicenter study of antimicrobial susceptibilities of Trichophyton rubrum and Trichophyton mentagrophytes strains causing tinea unguium. Antimicrob Agents Chemother 1995; 39: 1206-1208.
36. Lee KH, Kim YS, Kim MS, Chung HS, Park K. Study of the efficacy and tolerability of oral terbinafine in the treatment of onychomycosis in renal transplant patients. Transplant Proc 1996; 28: 1488-1498.
37. Marchetti A, Piech CT, McGhan WF, Neugut AI, Smith BT. Pharmacoeconomic analysis of oral therapies for onychomycosis: a US model. Clin Ther 1996; 18: 757-777.
38. Matsumoto T, Tanuma H, Kaneko S, Takasu H, Nishiyama S. Clinical and pharmacokinetic investigations of oral terbinafine in patients with tinea unguium. Mycoses 1995; 38: 135-144.
39. Nandwani R, Parnell A, Youle M et al. Use of terbinafine in HIV-positive subjects: pilot studies in onychomycosis and oral candidiasis. Br J Dermatol 1996; 134 (Suppl 46): 22-24.
40. Nolting S, Bräutigam M, Weidinger G. Terbinafine in onychomycosis with involvement by nondermatophyte fungi. Br J Dermatol 1994; 130 (Suppl 43): 16-21.
41. Piraccini BM, Morelli R, Stinchi C, Tosti A. Proximal subungual onychomycosis due to Microsporum canis. Br J Dermatol 1996; 134: 175-177.
42. Roberts DT. Prevalence of dermatophyte onychomycosis in the United Kingdom: results of an omnibus survey. Br J Dermatol 1992; 126 (Suppl 39): 23-27.
43. Roberts DT, Richardson MD, Dwyer PK. Terbinafine in chronic paronychia and Candida onychomycosis. J Dermatol Treat 1992; 3 (Suppl): 39-42.
44. Sais G, Juggla A, Peyri J. Prevalence of dermatophyte onychomycosis in Spain: a cross-sectional study. Br J Dermatol 1995; 132: 758-761.
45. Scher RK. Onychomycosis is more than a cosmetic problem. J Dermatol 1994; 130: 15.
46. Segal R, Guadelli L, Kritzmann A, David M. Treatment of Candida nail infection with terbinafine. Presented at 2nd Annual International Summit on Cutaneous Antifungal Therapy. Boston Massachusetts, November 10-13, 1994.
47. Shuster S, Munro CS. Single-dose treatment of fungal nail disease. Lancet 1992; 339: 1066.
48. Summerbell RC, Kane J, Krajden S. Onychomycosis, tinea pedis and tinea manuum caused by non-dermatophyte filamentous fungi. Mycoses 1989; 32: 609-619.
49. Tosti A, Piraccini BM, Stinchi C, Venturon N, Bardazzi F, Colombo MD. Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. J Am Acad Dermatol 1996a; 34: 595-600.
50. Tosti A, Priaccini BM, Stinchi C, Lorenzi S. Onychomycosis due to Scopulariopsis brevicaulis: clinical features and response to systemic antifungals. Br J Dermatol 1996b; 135: 799-802.
51. Van der Schroeflf JG, Girkel PKDS, Crijns MB et al. A randomised treatment duration finding study of terbinafine in onychomycosis. Br J Dermatol 1992; 126 (Suppl 39): 36-39.
52. Van Doorslaer EKA, Tormans G, Gupta AK et al. Economic evaluation of antifungal agents in the treatment of toenail onychomycosis in Germany. Dermatology 1996; 193: 239-244.
53. Velthuis PJ, Nijenhuis M. Treatment of onychomycosis with terbinafine in patients with Down's syndrome. Br J Dermatol 1995; 133: 144-145.
54. Villars W, Jones TC. Special features of the clinical use of terbinafine in the treatment of fungal diseases. Br J Dermatol 1992; 126 (Suppl 39): 61-69.
55. Watson A, Marley J, Ellis D, Williams T. Terbinafine in onychomycosis of the toenail: a novel treatment protocol. J Am Acad Dermatol 1995; 33: 775-779.
56. Willemsen M, De Doncker P, Willems J et al. Post-treatment itraconazole levels in nails. New implications for treatment in onychomycosis. J Am Acad Dermatol 1992; 26: 731-735.
57. Wong C-K, Cho Y-L. Very short duration therapy with oral terbinafine for fingernail onychomycosis. Br J Dermatol 1995; 133: 329-347.
58. Zaias N, Serrano L. The successful treatment of finger Trichophyton rubrum onychomycosis with oral terbinafine. Clin Exp Dermatol 1989; 14: 120-123.